Get the Stockscreener App
0.00
100.00%
-15.02
Definium Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
See More
Previous Close:
$15.02
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.48B
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
0.00
EPS:
-2.45
Net Cash Flow:
$-64.37M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
448.10 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.50 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.99 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.86 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.97 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (MNMD) Latest News
Definium Therapeutics stock hits 52-week high at 19.78 USD - Investing.com
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States - BioSpace
Definium Therapeutics (DFTX) Study Highlights Rising GAD Rates i - GuruFocus
Anxiety disorder prevalence rises to 6.6% in U.S., study finds By Investing.com - Investing.com Australia
Anxiety disorder prevalence rises to 6.6% in U.S., study finds - Investing.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart - Capital.com
Definium Therapeutics Announces New Employee Inducement Grants - Yahoo! Finance Canada
A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline - Sahm
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - Defense World
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics Insider Sold Shares Worth $451,241, According to a Recent SEC Filing - marketscreener.com
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 - BioSpace
Definium Therapeutics CMO Karlin sells $148k in shares By Investing.com - Investing.com Australia
Definium Therapeutics CEO Barrow sells $451k in shares By Investing.com - Investing.com India
Definium Therapeutics CEO Barrow sells $451k in shares - Investing.com
Definium Therapeutics CMO Karlin sells $148k in shares - Investing.com
Definium Therapeutics chief legal officer sells $197k in shares - Investing.com
Definium Therapeutics chief legal officer sells $197k in shares By Investing.com - Investing.com UK
Definium (NASDAQ: DFTX) CMO sells shares to cover RSU tax - Stock Titan
Tax-cover sale by Definium (DFTX) legal chief totals 10,702 shares - Stock Titan
Definium Therapeutics (DFTX) CEO share sale covers RSU tax withholding - Stock Titan
Definium Therapeutics brings Investor and Analyst Day event to New York - Traders Union
Robert Barrow files to sell 24,431 DFTX shares (DFTX) - Stock Titan
Affiliate sale notice for DFTX (NASDAQ: DFTX) — 8,018 shares reported - Stock Titan
Mark Sullivan to sell 10,702 shares (DFTX) under registered plan - Stock Titan
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 - Insider Monkey
9 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
A Look At Definium Therapeutics (DFTX) Valuation After Strong Recent Share Price Momentum - Sahm
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.66 USD By Investing.com - Investing.com South Africa
Definium Therapeutics stock hits 52-week high at 19.66 USD - Investing.com
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - MarketBeat
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
DFTX: Definium Therapeutics, Inc.Detailed Earnings Estimates - Zacks Investment Research
DFTX: Pivotal phase III data for DT-120 in GAD and MDD expected this year, targeting broad market impact - TradingView
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 earnings call transcript - MSN
Definium Therapeutics stock hits 52-week high at 18.71 USD By Investing.com - Investing.com Nigeria
Boxer Capital Management LLC Takes Position in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Teases Phase III DT120 Data for Anxiety, Depression at Leerink Conference - MarketBeat
Commodore Capital LP Lowers Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX - MarketBeat
Rosalind Advisors Inc. Has $8.84 Million Holdings in Definium Therapeutics, Inc. $DFTX - MarketBeat
Definium Therapeutics Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Definium Therapeutics Inc Stock (MNMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Mark | Chief Legal Officer |
Mar 25 '26 |
Sale |
18.47 |
10,702 |
197,666 |
271,079 |
| Barrow Robert | Chief Executive Officer |
Mar 25 '26 |
Sale |
18.47 |
24,431 |
451,241 |
752,454 |
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):